Canagliflozin Alleviates Diabetic Glomerular Endothelial Injury via Melibiose in a Microbiota‐Dependent Manner
Authors:
Open Access
- 27 May 2026
- journal article
- Published by Wiley in Advanced Science
- Vol. 13 (47) , e17222
Abstract
Canagliflozin reduces albuminuria in patients with diabetic kidney disease (DKD) beyond its glucose‐lowering effect, but the mechanisms remain unclear. We analyzed 85 patients treated with canagliflozin and 85 controls over 26 weeks to explore whether the gut microbiome and its metabolites contribute to renoprotection. Canagliflozin remodeled the gut microbiota, notably enriching Roseburia intestinalis and increasing plasma melibiose levels. In mice, canagliflozin alleviated glomerular endothelial injury and albuminuria. Similar effects were replicated by fecal microbiota transplantation, Roseburia intestinalis , or melibiose administration. Mechanistically, melibiose bound to and activated glyoxalase 1, reduced methylglyoxal, and suppressed the AGE‐RAGE pathway, preserving glomerular endothelial integrity. Furthermore, oral melibiose precursor supplementation reduced albuminuria in patients with early‐stage DKD. These findings suggest the involvement of a gut‐kidney axis in the renoprotective effects of canagliflozin and indicate that melibiose may serve as a potential therapeutic strategy for DKD.Keywords
Funding Information
- National Natural Science Foundation of China (82170839)
- National Natural Science Foundation of China (U23A20414)
- National Natural Science Foundation of China (82470876)
- National Natural Science Foundation of China (82300930)
- Natural Science Foundation of Henan Province (242300421272)
This publication has 57 references indexed in Scilit:
- Gut microbial alterations in arginine metabolism determine bone mechanical adaptationCell Metabolism, 2024
- Molecular mechanisms and therapeutic targets for diabetic kidney diseaseKidney International, 2022
- Empagliflozin protects glomerular endothelial cell architecture in experimental diabetes through the VEGF‐A /caveolin‐1/ PV ‐1 signaling pathwayThe Journal of Pathology, 2022
- AGE/RAGE in diabetic kidney disease and ageing kidneyFree Radical Biology and Medicine, 2021
- Large-scale targeted metabolomics method for metabolite profiling of human samplesAnalytica Chimica Acta, 2020
- Endothelin receptor-A mediates degradation of the glomerular endothelial surface layer via pathologic crosstalk between activated podocytes and glomerular endothelial cellsKidney International, 2019
- Hesperetin ameliorates diabetic nephropathy in rats by activating Nrf2/ARE/glyoxalase 1 pathwayBiomedicine & Pharmacotherapy, 2019
- AGE-RAGE axis blockade in diabetic nephropathy: Current status and future directionsEuropean Journal of Pharmacology, 2018
- Advanced glycation end products in the pathogenesis of chronic kidney diseaseKidney International, 2018
- Physiologically based pharmacokinetic–pharmacodynamic modeling to predict concentrations and actions of sodium‐dependent glucose transporter 2 inhibitor canagliflozin in human intestines and renal tubulesBiopharmaceutics & Drug Disposition, 2016